Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 8c, raises guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 EPS of $0.25, $0.08 better than the analyst estimate of $0.17. Revenue for the quarter came in at $725 million versus the consensus estimate of $748.18 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2025 EPS of $0.70-$0.75, versus the consensus of $0.71. Amneal Pharmaceuticals sees FY2025 revenue of $3-3.1 billion, versus the consensus of $3.017 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Cerebras Q1 EPS miss sends shares down 9% after-hours